EGFR tyrosine kinase inhibitors (EGF-TKI) intercept EGFR-mediated downstream signaling pathways (such as PI3K-AKT) via de-phosphorylation of Her3, while some lung carcinoma cell lines acquire resistance via amplification of MET [36]. Here, EGFR is linked to lung carcinoma.